Taken together, our results demonstrate that SPRY2-OE inhibits clathrin- and caveolin-1-mediated endocytosis of FGFR1 and reduces the amount of caveolin-1 as well as the uptake of transferrin into GBM cells. The gene discussed is CAV1; the disease is glioblastoma.